Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Piper says Inspire appears to have received FDA approval for expanded labeling » 11:35
07/05/22
07/05
11:35
07/05/22
11:35
INSP

Inspire Medical

$191.40 /

+1.5 (+0.79%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder points to a link to a PMA supplement dated July 1 that was posted to the FDA website to support his view that Inspire Medical Systems appears to have received approval for expanded labeling of its system to include 1.5 Tesla full-body MRI capabilities, though he also notes that has not been able to connect yet with the company to confirm. The analyst, who has heard multiple clinicians at the SLEEP meeting last month comment that the historical MRI labeling has been a barrier to Inspire Medical therapy adoption, believes some patients may be more inclined to move forward with a procedure with the new approval in-hand. Maeder keeps an Overweight rating and $310 price target on Inspire Medical shares.

ShowHide Related Items >><<
INSP Inspire Medical
$191.40 /

+1.5 (+0.79%)

INSP Inspire Medical
$191.40 /

+1.5 (+0.79%)

06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
05/04/22 Piper Sandler
Inspire Medical price target raised to $310 from $305 at Piper Sandler
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Inspire Medical initiated with a Buy at Truist
INSP Inspire Medical
$191.40 /

+1.5 (+0.79%)

Hot Stocks
Arrowhead initiates studies of pulmonary candidates ARO-MUC5AC and ARO-RAGE » 07:38
07/05/22
07/05
07:38
07/05/22
07:38
ARWR

Arrowhead

$35.97 /

+0.76 (+2.16%)

Arrowhead Pharmaceuticals…

Arrowhead Pharmaceuticals announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company's investigational RNA interference therapeutics designed to reduce production the of mucin 5AC and the receptor for advanced glycation end products , respectively, as potential treatments for various muco-obstructive and inflammatory pulmonary diseases. "Initiating clinical studies for ARO-MUC5AC and ARO-RAGE, Arrowhead's next generation pulmonary targeted RNAi therapeutic candidates, is a significant milestone for the company," said Chris Anzalone, Ph.D., president and chief executive officer of Arrowhead. "These are potentially important new medicines that address targets that have been difficult to drug using other modalities and are designed to treat muco-obstructive and inflammatory lung diseases in fundamentally new ways." AROMUC5AC-1001 is a Phase 1/2a, randomized, double-blinded, placebo-controlled study in up to 42 normal healthy volunteers and up to 16 patients with moderate-to-severe asthma. The single ascending dose portion of the study includes 3 sequentially enrolled NHV cohorts with escalating single-dose levels. The multiple ascending dose portion of the study includes 3 NHV cohorts and 2 asthma patient cohorts. The objectives of the study include the assessment of safety and tolerability, pharmacokinetics, and pharmacodynamics of ARO-MUC5AC in NHVs and patients with asthma.

ShowHide Related Items >><<
ARWR Arrowhead
$35.97 /

+0.76 (+2.16%)

ARWR Arrowhead
$35.97 /

+0.76 (+2.16%)

06/03/22 H.C. Wainwright
Arrowhead price target raised to $110 from $100 at H.C. Wainwright
05/11/22 Baird
Arrowhead upgraded to Outperform at Baird following pullback
05/11/22 Baird
Arrowhead upgraded to Outperform from Neutral at Baird
05/11/22 Piper Sandler
Arrowhead price target lowered to $72 from $89 at Piper Sandler
ARWR Arrowhead
$35.97 /

+0.76 (+2.16%)

ARWR Arrowhead
$35.97 /

+0.76 (+2.16%)

Over a week ago
Downgrade
Alnylam downgraded to Neutral from Buy at Guggenheim » 06:51
06/27/22
06/27
06:51
06/27/22
06:51
ALNY

Alnylam

$147.57 /

+1.375 (+0.94%)

Guggenheim analyst Debjit…

Guggenheim analyst Debjit Chattopadhyay downgraded Alnylam to Neutral from Buy with no price target, telling investors that proprietary analyses, complemented by talks with key opinion leaders, point to "uncertainties in ATTR-CM" and "a challenged outlook" for the APOLLO-B trial. Chattopadhyay sees an unfavorable risk/reward given the view that the APOLLO-B outcome is "a coin flip," but hopes to be wrong with the cautious outlook as "we are believers in the superiority of silencers over stabilizers," the analyst tells investors.

ShowHide Related Items >><<
ALNY Alnylam
$147.57 /

+1.375 (+0.94%)

ALNY Alnylam
$147.57 /

+1.375 (+0.94%)

06/21/22 Piper Sandler
Ionis told Piper eplontersen efficacy competitive with Amvuttra
06/15/22 Citi
Citi opens positive '90-day Catalyst Watch' Alnylam after approval
06/14/22 Piper Sandler
Piper bullish on Alnylam as FDA approves AMVUTTRA for hATTR Polyneuropathy
ALNY Alnylam
$147.57 /

+1.375 (+0.94%)

ALNY Alnylam
$147.57 /

+1.375 (+0.94%)

Hot Stocks
Takeda, Arrowhead announce results from Phase 2 study of fazirsiran » 06:02
06/27/22
06/27
06:02
06/27/22
06:02
TAK

Takeda Pharmaceutical

$13.84 /

+0.1 (+0.73%)

, ARWR

Arrowhead

$34.46 /

+0.18 (+0.53%)

Takeda (TAK) and…

Takeda (TAK) and Arrowhead Pharmaceuticals (ARWR) announced that results from a Phase 2 clinical study of investigational fazirsiran for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, AATD, were recently published in the New England Journal of Medicine, NEJM, and presented in an oral presentation at The International Liver Congress 2022 - The Annual Meeting of the European Association for the Study of the Liver, EASL. The NEJM article was published online ahead of print and is titled, "Fazirsiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency." The EASL presentation was titled, "Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency." Fazirsiran is a potential first-in-class investigational RNA interference therapy designed to reduce the production of mutant alpha-1 antitrypsin protein as a potential treatment for the rare genetic liver disease associated with AATD. Z-AAT accumulation is believed to be the cause of progressive liver disease in patients with AATD. "The exciting data on fazirsiran treatment from the open label AROAAT-2002 Phase 2 study in patients with AATD liver disease suggest a treatment effect and the potential to improve multiple downstream markers of liver health. We are also nearing completion of the Phase 2 SEQUOIA study and we look forward to further assessing the potential of fazirsiran in this larger placebo-controlled study," said Javier San Martin, M.D., Chief Medical Officer at Arrowhead. "Fazirsiran has shown a high level of activity across all patients studied and is representative of how the RNA interference pathway can be leveraged to reliably and consistently silence gene expression and potentially have a positive impact on patients with various genetic diseases."

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$13.84 /

+0.1 (+0.73%)

ARWR Arrowhead
$34.46 /

+0.18 (+0.53%)

TAK Takeda Pharmaceutical
$13.84 /

+0.1 (+0.73%)

05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
03/31/22 Canaccord
Canaccord starts Morphic at Buy, sees potential to take share from Takeda
02/11/22 BTIG
Protagonist Therapeutics initiated with a Buy at BTIG
02/11/22 BTIG
Morphic initiated with a Buy at BTIG
ARWR Arrowhead
$34.46 /

+0.18 (+0.53%)

06/03/22 H.C. Wainwright
Arrowhead price target raised to $110 from $100 at H.C. Wainwright
05/11/22 Baird
Arrowhead upgraded to Outperform at Baird following pullback
05/11/22 Baird
Arrowhead upgraded to Outperform from Neutral at Baird
05/11/22 Piper Sandler
Arrowhead price target lowered to $72 from $89 at Piper Sandler
ARWR Arrowhead
$34.46 /

+0.18 (+0.53%)

TAK Takeda Pharmaceutical
$13.84 /

+0.1 (+0.73%)

TAK Takeda Pharmaceutical
$13.84 /

+0.1 (+0.73%)

ARWR Arrowhead
$34.46 /

+0.18 (+0.53%)

Recommendations
Ionis told Piper eplontersen efficacy competitive with Amvuttra » 12:20
06/21/22
06/21
12:20
06/21/22
12:20
IONS

Ionis Pharmaceuticals

$37.35 /

+2.02 (+5.72%)

, ALNY

Alnylam

$139.63 /

+2.5 (+1.82%)

Piper Sandler analyst Do…

Piper Sandler analyst Do Kim keeps an Overweight rating on Ionis Pharmaceuticals (IONS) with a $55 price target after the company announced eplontersen met the co-primary and secondary endpoints for the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy. The company released no detailed data but in a call with management, it confirmed eplonterson efficacy and safety was competitive with Alnylam's (ALNY) Amvuttra, Kim tells investors in a research note. He expects an FDA filing in the second half of 2022 to support approval in hATTR-PN in the second half of 2023.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$37.35 /

+2.02 (+5.72%)

ALNY Alnylam
$139.63 /

+2.5 (+1.82%)

IONS Ionis Pharmaceuticals
$37.35 /

+2.02 (+5.72%)

06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
05/05/22 Stifel
Ionis Pharmaceuticals price target raised to $33 from $31 at Stifel
05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/29/22 Piper Sandler
Piper pushes out eplonterson estimates after Ionis study changes
ALNY Alnylam
$139.63 /

+2.5 (+1.82%)

06/15/22 Citi
Citi opens positive '90-day Catalyst Watch' Alnylam after approval
06/14/22 Piper Sandler
Piper bullish on Alnylam as FDA approves AMVUTTRA for hATTR Polyneuropathy
06/07/22 William Blair
Alnylam initiated with an Outperform at William Blair
IONS Ionis Pharmaceuticals
$37.35 /

+2.02 (+5.72%)

ALNY Alnylam
$139.63 /

+2.5 (+1.82%)

IONS Ionis Pharmaceuticals
$37.35 /

+2.02 (+5.72%)

ALNY Alnylam
$139.63 /

+2.5 (+1.82%)

Recommendations
Citi opens positive '90-day Catalyst Watch' Alnylam after approval » 06:02
06/15/22
06/15
06:02
06/15/22
06:02
ALNY

Alnylam

$133.68 /

+6.06 (+4.75%)

Citi analyst David…

Citi analyst David Lebowitz opens a "90-day Catalyst Watch" on Alnylam Pharmaceuticals after the company announced approval for Amvuttra for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The approval removes one overhang from the shares, and investors can now turn their attention to the upcoming Phase III APOLLO-B update for Onpattro, Lebowitz tells investors in a research note. The analyst believes the trial will report in Alnylam's favor and support FDA approval for the indication. He keeps a Buy rating on the shares with a $211 price target.

ShowHide Related Items >><<
ALNY Alnylam
$133.68 /

+6.06 (+4.75%)

ALNY Alnylam
$133.68 /

+6.06 (+4.75%)

06/14/22 Piper Sandler
Piper bullish on Alnylam as FDA approves AMVUTTRA for hATTR Polyneuropathy
06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
06/07/22 William Blair
Alnylam initiated with an Outperform at William Blair
05/02/22 H.C. Wainwright
Alnylam price target raised to $430 from $400 at H.C. Wainwright
ALNY Alnylam
$133.68 /

+6.06 (+4.75%)

ALNY Alnylam
$133.68 /

+6.06 (+4.75%)

Recommendations
Piper bullish on Alnylam as FDA approves AMVUTTRA for hATTR Polyneuropathy » 10:51
06/14/22
06/14
10:51
06/14/22
10:51
ALNY

Alnylam

$134.55 /

+6.925 (+5.43%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $208 price target on Alnylam, noting that the FDA approved 25mg quarterly subcutaneous AMVUTTRA for the treatment of hereditary ATTR amyloidosis with polyneuropathy based on positive Phase III HELIOSA data. The analyst believes less frequent subcutaneous AMVUTTRA will cannibalize some intravenous ONPATTRO, but still grow the overall market for Alnylam. Alnylam maintained guided 2022 product sales of $870M-$930M, and Tenthoff inched up his forecast to $867M due to earlier approval and higher than anticipated price. The primary driver for Alnylam shares remains Phase III APOLLO-B data on ONPATTRO in mid-2022, he adds.

ShowHide Related Items >><<
ALNY Alnylam
$134.55 /

+6.925 (+5.43%)

ALNY Alnylam
$134.55 /

+6.925 (+5.43%)

06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
06/07/22 William Blair
Alnylam initiated with an Outperform at William Blair
05/02/22 H.C. Wainwright
Alnylam price target raised to $430 from $400 at H.C. Wainwright
04/29/22 Citi
Alnylam price target lowered to $211 from $223 at Citi
ALNY Alnylam
$134.55 /

+6.925 (+5.43%)

ALNY Alnylam
$134.55 /

+6.925 (+5.43%)

Hot Stocks
Alnylam announces FDA approval of AMVUTTRA » 19:28
06/13/22
06/13
19:28
06/13/22
19:28
ALNY

Alnylam

$127.62 /

-4.67 (-3.53%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals "announced that the FDA approved AMVUTTRA, or vutrisiran, an RNAi therapeutic administered via subcutaneous injection once every three months for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The FDA approval is based on positive 9-month results from the HELIOS-A Phase 3 study, where AMVUTTRA significantly improved the signs and symptoms of polyneuropathy, with more than 50 percent of patients experiencing halting or reversal of their disease manifestations. The FDA approval of AMVUTTRA is based on positive 9-month results from HELIOS-A, a global, randomized, open-label, multicenter, Phase 3 study that evaluated the efficacy and safety of AMVUTTRA across a diverse group of patients with hATTR amyloidosis with polyneuropathy. 164 patients with hATTR amyloidosis were randomized 3:1 to receive either 25 mg of vutrisiran via subcutaneous injection once every three months or 0.3 mg/kg of patisiran via intravenous infusion once every three weeks for 18 months. The efficacy of AMVUTTRA was assessed by comparing the AMVUTTRA group in HELIOS-A with the placebo group from the landmark APOLLO Phase 3 study of patisiran, a randomized controlled study in a comparable patient population."

ShowHide Related Items >><<
ALNY Alnylam
$127.62 /

-4.67 (-3.53%)

ALNY Alnylam
$127.62 /

-4.67 (-3.53%)

06/10/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler
06/07/22 William Blair
Alnylam initiated with an Outperform at William Blair
05/02/22 H.C. Wainwright
Alnylam price target raised to $430 from $400 at H.C. Wainwright
04/29/22 Citi
Alnylam price target lowered to $211 from $223 at Citi
ALNY Alnylam
$127.62 /

-4.67 (-3.53%)

ALNY Alnylam
$127.62 /

-4.67 (-3.53%)

Recommendations
Ionis Pharmaceuticals price target raised to $55 from $54 at Piper Sandler » 13:54
06/10/22
06/10
13:54
06/10/22
13:54
IONS

Ionis Pharmaceuticals

$34.37 /

-0.57 (-1.63%)

, ALNY

Alnylam

$133.13 /

-1.89 (-1.40%)

Piper Sandler analyst Do…

Piper Sandler analyst Do Kim raised the firm's price target on Ionis Pharmaceuticals (IONS) to $55 from $54 and keeps an Overweight rating on the shares. The analyst updated his model following the firm's conversation with management, saying the cadence of his quarterly estimates better aligns with Ionis expectations, with Q2 revenues similar to Q1 and H2 revenues more weighted to year-end. Kim added that he believes Alynylam's (ALNY) Onpattro APOLLO-B data in ATTR-Cm expected in mid-year 2022 could have potential read through to Ionis shares.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$34.37 /

-0.57 (-1.63%)

ALNY Alnylam
$133.13 /

-1.89 (-1.40%)

IONS Ionis Pharmaceuticals
$34.37 /

-0.57 (-1.63%)

05/05/22 Stifel
Ionis Pharmaceuticals price target raised to $33 from $31 at Stifel
05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/29/22 Piper Sandler
Piper pushes out eplonterson estimates after Ionis study changes
03/30/22 Piper Sandler
Ionis Pharmaceuticals assumed with an Overweight at Piper Sandler
ALNY Alnylam
$133.13 /

-1.89 (-1.40%)

06/07/22 William Blair
Alnylam initiated with an Outperform at William Blair
05/02/22 H.C. Wainwright
Alnylam price target raised to $430 from $400 at H.C. Wainwright
04/29/22 Citi
Alnylam price target lowered to $211 from $223 at Citi
04/25/22 Morgan Stanley
Alnylam downgraded to Equal Weight from Overweight at Morgan Stanley
IONS Ionis Pharmaceuticals
$34.37 /

-0.57 (-1.63%)

ALNY Alnylam
$133.13 /

-1.89 (-1.40%)

IONS Ionis Pharmaceuticals
$34.37 /

-0.57 (-1.63%)

ALNY Alnylam
$133.13 /

-1.89 (-1.40%)

Recommendations
Inspire Medical price target lowered to $250 from $296 at Truist » 07:09
06/10/22
06/10
07:09
06/10/22
07:09
INSP

Inspire Medical

$186.23 /

-3.2 (-1.69%)

Truist analyst Richard…

Truist analyst Richard Newitter lowered the firm's price target on Inspire Medical to $250 from $296 but keeps a Buy rating on the shares. His discussion with sleep specialists and ENT Inspire users at this week's SLEEP 2022 event have left him positive on Inspire volume trends and the hypoglossal nerve stimulation awareness, the analyst tells investors in a research note. Newitter adds that he remains positive on the company and its "durable" 30%-45% revenue growth with 85% or more gross margin profile.

ShowHide Related Items >><<
INSP Inspire Medical
$186.23 /

-3.2 (-1.69%)

INSP Inspire Medical
$186.23 /

-3.2 (-1.69%)

05/04/22 Piper Sandler
Inspire Medical price target raised to $310 from $305 at Piper Sandler
04/12/22 Truist
Truist starts six stocks in Medical Supplies and Devices, assumes eight others
04/12/22 Truist
Inspire Medical initiated with a Buy at Truist
04/05/22 Wolfe Research
Inspire Medical initiated with a Peer Perform at Wolfe Research
INSP Inspire Medical
$186.23 /

-3.2 (-1.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.